APUS

NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Dollar change -0.03
Percentage change -1.73	%

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.11	Insider Own	68.51%	Shs Outstand	11.70M	Perf Week	-22.73%
Market Cap	19.67M	Forward P/E	-	EPS next Y	-	Insider Trans	7.54%	Shs Float	3.64M	Perf Month	-
Income	-1.39M	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Book/sh	-0.12	P/B	-	EPS next Y	-	ROA	-638.88%	Short Interest	-	Perf Year	-
Cash/sh	0.00	P/C	-	EPS next 5Y	-	ROE	-	52W Range	1.44 - 4.00	Perf YTD	-22.73%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-57.50%	Beta	-
Dividend TTM	-	Quick Ratio	0.01	Sales past 5Y	0.00%	Gross Margin	-	52W Low	18.06%	ATR (14)	0.63
Dividend Ex-Date	-	Current Ratio	0.01	EPS Y/Y TTM	-82.06%	Oper. Margin	-	RSI (14)	-	Volatility	22.59% -
Employees	2	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	40.49%	Payout	-	Rel Volume	0.13	Prev Close	1.73
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	589.32K	Price	1.70
SMA20	-7.69%	SMA50	-7.69%	SMA200	-7.69%	Trades		Volume	77,196	Change	-1.73%

May-12-25 05:14PM	Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering (GlobeNewswire) -17.73%
May-08-25 05:00PM	Apimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public Offering (GlobeNewswire)

Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. It primarily focuses on developing innovative therapies for inflammation and pain management in knee osteoarthritis (OA) and, to a lesser extent, multiple sclerosis (MS). The company was founded on May 11, 2020 and is headquartered in Hopewell, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kim Christopher	Chairman and CMO	May 13 '25	Buy	1.82	19,770	35,981	19,770	May 15 06:48 PM
Kim Christopher	Chairman and CMO	May 14 '25	Buy	1.86	7,730	14,378	27,500	May 15 06:48 PM
Koo Jakap	Director	May 12 '25	Buy	1.99	28,500	56,715	643,885	May 14 05:58 PM
Inscobee Inc.	10% Owner	May 12 '25	Buy	4.00	500,000	2,000,000	1,984,616	May 14 05:52 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Apimeds Pharmaceuticals US Inc

Upgrade your FINVIZ experience